Company profile: Rejuveron
1.1 - Company Overview
Company description
- Provider of a fully integrated biotechnology platform that invests in people and ideas to develop therapies and technologies to improve healthy aging and prolong lifespan.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Rejuveron
Centessa Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies and platforms, including SerpinPC, a biologic for hemophilia that inhibits activated protein C to reduce bleeding; an Orexin Receptor 2 agonist program for sleep-wake disorders; the LockBody technology platform designed to enhance immuno-oncology by selectively targeting the tumor microenvironment; and LB101, a conditionally tetravalent PD-L1 X CD47 bispecific monoclonal antibody for advanced solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Centessa Pharmaceuticals company profile →
Manhattan Pharma
HQ: United States
Website
- Description: Provider of specialty healthcare product development and commercialization focused on innovative treatments for underserved patient populations, advancing a portfolio of product candidates.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Manhattan Pharma company profile →
Salix Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty pharmaceuticals focused on preventing and treating gastrointestinal disorders, licensing, developing, and marketing therapies including XIFAXAN for IBS-D and reducing overt hepatic encephalopathy recurrence; RELISTOR for opioid-induced constipation; TRULANCE for chronic idiopathic constipation and IBS-C; UCERIS for ulcerative colitis; MOVIPREP and PLENVU for colonoscopy bowel preparation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Salix Pharmaceuticals company profile →
Navitor Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel medicines targeting nutrient-sensing proteins, including NV-5138, an orally bioavailable small molecule that directly activates mTORC1 for treatment-resistant depression, and AT-20494, a selective mTORC1 inhibitor for autosomal dominant polycystic kidney disease and potentially other conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Navitor Pharmaceuticals company profile →
Instil Bio
HQ: United States
Website
- Description: Provider of cell therapy solutions focused on tumor infiltrating lymphocytes (TIL) for the treatment of solid tumor cancers, advancing proprietary manufacturing expertise, technology, and data into clinical trials. Programs include a planned registrational study and a first-in-human next-generation engineered TIL, plus FRα CoStAR, a clinical-stage candidate for non-small cell lung cancer (NSCLC).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Instil Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Rejuveron
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Rejuveron
2.2 - Growth funds investing in similar companies to Rejuveron
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Rejuveron
4.2 - Public trading comparable groups for Rejuveron
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →